Paulina J. Dziubańska-Kusibab
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paulina J. Dziubańska-Kusibab has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Bernard Haendler
Research and Early Development Oncology, Pharmaceuticals, Bayer AG, Müllerstr. 178, 13353 Berlin, Germany
2 shared publications - Ekaterina Nevedomskaya
Research and Early Development Oncology, Pharmaceuticals, Bayer AG, Müllerstr. 178, 13353 Berlin, Germany
1 shared publication - Thibaud Jourdan
Research and Early Development Oncology, Pharmaceuticals, Bayer AG, Müllerstr. 178, 13353 Berlin, Germany
1 shared publication
Latest Publications
- Open Access
- 15 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8200
Targeting the Androgen Receptor and Associated Cofactors in Prostate Cancer: Novel Approaches and Future Perspectives
Following the first approval for prostate cancer (PCa) treatment of competitive antagonists of the androgen receptor (AR) function that bind to the androgen-binding pocket, much progress has been achieved regarding compound efficacy and specificity. Second-generation compounds and androgen synthesis blockers are now standard-of-care AR pathway inhibitors given to PCa patients. More recently, approaches targeting AR regions other than the ligand-binding domain (LBD), stimulating proteasome-mediated AR degradation, or bringing together the AR with an effector protein (EP) in prostate tumor cells, have been explored and, in several cases, clinically tested. Compounds blocking AR mRNA splicing or directly addressing AR splice variants, especially the constitutively active AR-V7 form, are also being evaluated. In addition, there are ongoing efforts aiming at impairing the function of essential AR cofactors, mainly those involved in downstream gene transcription and chromatin modulation. Alternative techniques to impair AR activity, such as nanoparticle formulations and targeting biomolecular condensates are furthermore being explored. Here we present the most recent developments in these different strategies to target the AR, directly or indirectly, for a more potent and long-lasting blockade. This will hopefully soon lead to treatments that improve progression-free and overall survival in PCa patients, while maintaining a good safety profile.
- 15 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8200
Open AccessTargeting the Androgen Receptor and Associated Cofactors in Prostate Cancer: Novel Approaches and Future Perspectives
Following the first approval for prostate cancer (PCa) treatment of competitive antagonists of the androgen receptor (AR) function that bind to the androgen-binding pocket, much progress has been achieved regarding compound efficacy and specificity. Second-generation compounds and androgen synthesis blockers are now standard-of-care AR pathway inhibitors given to PCa patients. More recently, approaches targeting AR regions other than the ligand-binding domain (LBD), stimulating proteasome-mediated AR degradation, or bringing together the AR with an effector protein (EP) in prostate tumor cells, have been explored and, in several cases, clinically tested. Compounds blocking AR mRNA splicing or directly addressing AR splice variants, especially the constitutively active AR-V7 form, are also being evaluated. In addition, there are ongoing efforts aiming at impairing the function of essential AR cofactors, mainly those involved in downstream gene transcription and chromatin modulation. Alternative techniques to impair AR activity, such as nanoparticle formulations and targeting biomolecular condensates are furthermore being explored. Here we present the most recent developments in these different strategies to target the AR, directly or indirectly, for a more potent and long-lasting blockade. This will hopefully soon lead to treatments that improve progression-free and overall survival in PCa patients, while maintaining a good safety profile.
- Open Access
- 5 January 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (2) , 705
Preclinical Anticipation of On- and Off-Target Resistance Mechanisms to Anti-Cancer Drugs: A Systematic Review
The advent of targeted therapies has led to tremendous improvements in treatment options and their outcomes in the field of oncology. Yet, many cancers outsmart precision drugs by developing on-target or off-target resistance mechanisms. Gaining the ability to resist treatment is the rule rather than the exception in tumors, and it remains a major healthcare challenge to achieve long-lasting remission in most cancer patients. Here, we discuss emerging strategies that take advantage of innovative high-throughput screening technologies to anticipate on- and off-target resistance mechanisms before they occur in treated cancer patients. We divide the methods into non-systematic approaches, such as random mutagenesis or long-term drug treatment, and systematic approaches, relying on the clustered regularly interspaced short palindromic repeats (CRISPR) system, saturated mutagenesis, or computational methods. All these new developments, especially genome-wide CRISPR-based screening platforms, have significantly accelerated the processes for identification of the mechanisms responsible for cancer drug resistance and opened up new avenues for future treatments.
- 5 January 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (2) , 705
Open AccessPreclinical Anticipation of On- and Off-Target Resistance Mechanisms to Anti-Cancer Drugs: A Systematic Review
The advent of targeted therapies has led to tremendous improvements in treatment options and their outcomes in the field of oncology. Yet, many cancers outsmart precision drugs by developing on-target or off-target resistance mechanisms. Gaining the ability to resist treatment is the rule rather than the exception in tumors, and it remains a major healthcare challenge to achieve long-lasting remission in most cancer patients. Here, we discuss emerging strategies that take advantage of innovative high-throughput screening technologies to anticipate on- and off-target resistance mechanisms before they occur in treated cancer patients. We divide the methods into non-systematic approaches, such as random mutagenesis or long-term drug treatment, and systematic approaches, relying on the clustered regularly interspaced short palindromic repeats (CRISPR) system, saturated mutagenesis, or computational methods. All these new developments, especially genome-wide CRISPR-based screening platforms, have significantly accelerated the processes for identification of the mechanisms responsible for cancer drug resistance and opened up new avenues for future treatments.